3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Melanoma
21
Neoplasms
6
Carcinoma, Hepatocellular
5
Stomach Neoplasms
4
Recurrence
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Cancer
4
Uveal Melanoma
3
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Liver Neoplasms
3
Colonic Neoplasms
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Glioma
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Basal Cell
2
Brain Neoplasms
2
Interventions
Rituximab
295
Cyclophosphamide
240
Peripheral Blood Stem Cell Transplantation
114
fludarabine phosphate
110
Filgrastim
93
Etoposide
85
Radiotherapy
81
Lenalidomide
79
Vincristine
78
Prednisone
77
Mycophenolic Acid
66
Doxorubicin
61
Cyclosporine
59
Whole-Body Irradiation
58
Bendamustine Hydrochloride
58
Melphalan
57
Tacrolimus
53
Busulfan
51
fludarabine
50
Cytarabine
48
obinutuzumab
46
Methotrexate
45
Antilymphocyte Serum
43
Bortezomib
42
Methylprednisolone
37
Carmustine
37
sargramostim
36
ibritumomab tiuxetan
32
ibrutinib
30
Dexamethasone
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoma, Follicular
×
relatlimab
×
Clear all
NCT03310619
2024-04-04
PLATFORM
Celgene
Phase 1/2
Completed
62 enrolled
41 charts